HLN
Haleon plc
$8.87
0.05
(0.51%)
| Exchange: | |
| Market Cap: | 40.166B |
| Shares Outstanding: | 9.235B |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – Specialty & Generic | |||||
| CEO: | Brian James McNamara | |||||
| Full Time Employees: | 24561 | |||||
| Address: |
|
|||||
| Website: | https://www.haleon.com |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
